Wang Yongdong, Wang Jing, Zhang Xinyin, Xia Chengyan, Wang Zhiping
Department of Neurology, Chengdu Shuangliu District Hospital of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Front Genet. 2024 May 15;15:1400387. doi: 10.3389/fgene.2024.1400387. eCollection 2024.
Currently, an increasing body of research suggests that blood-based long non-coding RNAs (lncRNAs) could serve as biomarkers for diagnosing multiple sclerosis (MS). This meta-analysis evaluates the diagnostic capabilities of selected lncRNAs in distinguishing individuals with MS from healthy controls and in differentiating between the relapsing and remitting phases of the disease.
We conducted comprehensive searches across seven databases in both Chinese and English to identify relevant studies, applying stringent inclusion and exclusion criteria. The quality of the selected references was rigorously assessed using the QUADAS-2 tool. The analysis involved calculating summarized sensitivity (SSEN), specificity (SSPE), positive likelihood ratio (SPLR), negative likelihood ratio (SNLR), and diagnostic odds ratio (DOR) with 95% confidence intervals (CIs). Accuracy was assessed using summary receiver operating characteristic (SROC) curves.
Thirteen high-quality studies were selected for inclusion in the meta-analysis. Our meta-analysis assessed the combined diagnostic performance of lncRNAs in distinguishing MS patients from healthy controls. We found a SSEN of 0.81 (95% CI: 0.74-0.87), SSPE of 0.84 (95% CI: 0.78-0.89), SPLR of 5.14 (95% CI: 3.63-7.28), SNLR of 0.22 (95% CI: 0.16-0.31), and DOR of 23.17 (95% CI: 14.07-38.17), with an AUC of 0.90 (95% CI: 0.87-0.92). For differentiating between relapsing and remitting MS, the results showed a SSEN of 0.79 (95% CI: 0.71-0.85), SSPE of 0.76 (95% CI: 0.64-0.85), SPLR of 3.34 (95% CI: 2.09-5.33), SNLR of 0.28 (95% CI: 0.19-0.40), and DOR of 12.09 (95% CI: 5.70-25.68), with an AUC of 0.84 (95% CI: 0.81-0.87).
This analysis underscores the significant role of lncRNAs as biomarkers in MS diagnosis and differentiation between its relapsing and remitting forms.
目前，越来越多的研究表明，血液中的长链非编码RNA（lncRNA）可作为诊断多发性硬化症（MS）的生物标志物。本荟萃分析评估了所选lncRNA在区分MS患者与健康对照以及区分疾病复发和缓解阶段方面的诊断能力。
我们对七个中英文数据库进行了全面检索，以识别相关研究，并应用严格的纳入和排除标准。使用QUADAS-2工具对所选参考文献的质量进行了严格评估。分析包括计算汇总敏感性（SSEN）、特异性（SSPE）、阳性似然比（SPLR）、阴性似然比（SNLR）和诊断比值比（DOR）以及95%置信区间（CI）。使用汇总受试者工作特征（SROC）曲线评估准确性。
13项高质量研究被纳入荟萃分析。我们的荟萃分析评估了lncRNA在区分MS患者与健康对照方面的综合诊断性能。我们发现SSEN为0.81（95%CI：0.74-0.87），SSPE为0.84（95%CI：0.78-0.89），SPLR为5.14（95%CI：3.63-7.28），SNLR为0.22（95%CI：0.16-0.31），DOR为23.17（95%CI：14.07-38.17），AUC为0.90（95%CI：0.87-0.92）。对于区分复发型和缓解型MS，结果显示SSEN为0.79（95%CI：0.71-0.85），SSPE为0.76（95%CI：0.64-0.85），SPLR为3.34（95%CI：2.09-5.33），SNLR为0.28（95%CI：0.19-0.40），DOR为12.09（95%CI：5.70-25.68），AUC为0.84（95%CI：0.81-0.87）。
本分析强调了lncRNA作为生物标志物在MS诊断及其复发和缓解形式区分中的重要作用。
